{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:55:36Z","timestamp":1789016136038,"version":"build-2803163510"},"reference-count":66,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Contractes Cl\u00ednic de Recerca Emili Letang-Josep Font 2021","award":["FIS PI19\/01476"],"award-info":[{"award-number":["FIS PI19\/01476"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII)","doi-asserted-by":"publisher","award":["FIS PI19\/01476"],"award-info":[{"award-number":["FIS PI19\/01476"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the European Union","award":["FIS PI19\/01476"],"award-info":[{"award-number":["FIS PI19\/01476"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite emerging molecular information on chronic myelomonocytic leukemia (CMML), patient outcome remains unsatisfactory and little is known about the transformation to acute myeloid leukemia (AML). In a single-center cohort of 219 CMML patients, we explored the potential correlation between clinical features, gene mutations, and treatment regimens with overall survival (OS) and clonal evolution into AML. The most commonly detected mutations were TET2, SRSF2, ASXL1, and RUNX1. Median OS was 34 months and varied according to age, cytogenetic risk, FAB, CPSS and CPSS-Mol categories, and number of gene mutations. Hypomethylating agents were administered to 37 patients, 18 of whom responded. Allogeneic stem cell transplantation (alloSCT) was performed in 22 patients. Two-year OS after alloSCT was 60.6%. Six patients received targeted therapy with IDH or FLT3 inhibitors, three of whom attained a long-lasting response. AML transformation occurred in 53 patients and the analysis of paired samples showed changes in gene mutation status. Our real-world data emphasize that the outcome of CMML patients is still unsatisfactory and alloSCT remains the only potentially curative treatment. However, targeted therapies show promise in patients with specific gene mutations. Complete molecular characterization can help to improve risk stratification, understand transformation, and personalize therapy.<\/jats:p>","DOI":"10.3390\/cancers14174107","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T21:28:12Z","timestamp":1661462892000},"page":"4107","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-4665","authenticated-orcid":false,"given":"Sandra","family":"Casta\u00f1o-D\u00edez","sequence":"first","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medical School, University of Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-0178","authenticated-orcid":false,"given":"M\u00f3nica","family":"L\u00f3pez-Guerra","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bosch-Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Medical School, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2745","authenticated-orcid":false,"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medical School, University of Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Josep Carreras Leukemia Research Institute, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4777-9643","authenticated-orcid":false,"given":"Paola","family":"Charry","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Esteban","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-0929","authenticated-orcid":false,"given":"Francesca","family":"Guijarro","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medical School, University of Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Jim\u00e9nez-Vicente","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-8621","authenticated-orcid":false,"given":"Carlos","family":"Castillo-Gir\u00f3n","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-901X","authenticated-orcid":false,"given":"Albert","family":"Cortes","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Hematology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-5356","authenticated-orcid":false,"given":"Alexandra","family":"Mart\u00ednez-Roca","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Triguero","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"\u00c1lamo","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Be\u00e0","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Costa","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7486-8484","authenticated-orcid":false,"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rozman","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Medical School, University of Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Josep Carreras Leukemia Research Institute, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[{"name":"Hematology and Hematopathology Departments, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Josep Carreras Leukemia Research Institute, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Arber, D.A., Hasserjian, R.P., and Le Beau, M.M. (2017). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1182\/blood.V124.21.4645.4645","article-title":"Trends in Incidence, Primary Treatment and Survival of Chronic Myelomonocytic Leukemia: A Nationwide Population-Based Study Among 1359 Patients Diagnosed in the Netherlands from 1989 to 2012","volume":"124","author":"Dinmohamed","year":"2014","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428194.2016.1243681","article-title":"Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia","volume":"58","author":"Zahid","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41375-021-01207-3","article-title":"Chronic myelomonocytic leukemia diagnosis and management","volume":"35","author":"Chan","year":"2021","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00508-019-1526-1","article-title":"The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): A representative and useful real-life data source for further biomedical research","volume":"131","author":"Geissler","year":"2019","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/ejh.13768","article-title":"Multistep pathogenesis of chronic myelomonocytic leukemia in patients","volume":"109","author":"Geissler","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41375-018-0143-8","article-title":"Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases","volume":"32","author":"Patnaik","year":"2018","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12185-021-03210-x","article-title":"Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance","volume":"115","author":"Han","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/leu.2017.164","article-title":"Genomic determinants of chronic myelomonocytic leukemia","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/bloodadvances.2020003600","article-title":"A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation","volume":"5","author":"Gagelmann","year":"2021","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41408-020-00387-y","article-title":"Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia","volume":"10","author":"Pophali","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2008.366","article-title":"Outcome of allo-SCT for chronic myelomonocytic leukemia","volume":"43","author":"Ocheni","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1705369","article-title":"Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia","volume":"37","author":"Elliott","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Zabelina","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ajh.26455","article-title":"Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Patnaik","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","article-title":"How I treat chronic myelomonocytic leukemia","volume":"130","author":"Solary","year":"2017","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41375-021-01330-1","article-title":"Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia","volume":"35","author":"Renneville","year":"2021","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E433","DOI":"10.1002\/ajh.26334","article-title":"Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia","volume":"96","author":"Saliba","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-021-01240-2","article-title":"Activity of venetoclax-based therapy in chronic myelomonocytic leukemia","volume":"35","author":"Hammond","year":"2021","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/14728214.2020.1854224","article-title":"Emerging drugs for the treatment of chronic myelomonocytic leukemia","volume":"25","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000516655","article-title":"Re: International System for Human Cytogenetic or Cytogenomic Nomenclature (ISCN): Some Thoughts, by T. Liehr","volume":"161","author":"Hastings","year":"2021","journal-title":"Cytogenet. Genome Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: Relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","article-title":"Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)","volume":"96","author":"Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin. Trials"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/bmt.2012.282","article-title":"Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation","volume":"48","author":"Iacobelli","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ejh.13647","article-title":"Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia","volume":"107","author":"Jager","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2352-3026(20)30374-4","article-title":"Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: A retrospective cohort study","volume":"8","author":"Pleyer","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.leukres.2015.05.017","article-title":"Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML","volume":"39","author":"Calvo","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2018.05.003","article-title":"The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS","volume":"70","author":"Xicoy","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s12185-017-2243-z","article-title":"CMML: Clinical and molecular aspects","volume":"105","author":"Itzykson","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2015.337","article-title":"Age-related mutations and chronic myelomonocytic leukemia","volume":"30","author":"Mason","year":"2016","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-017-0045-4","article-title":"EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental","volume":"8","author":"Patnaik","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s12094-021-02585-x","article-title":"Mutations in chronic myelomonocytic leukemia and their prognostic relevance","volume":"23","author":"Jian","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","article-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients","volume":"34","author":"Coltro","year":"2020","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Heibl, S., Gisslinger, B., Jager, E., Barna, A., Gurbisz, M., Stegemann, M., Bettelheim, P., Machherndl-Spandl, S., Pfeilstocker, M., and Nosslinger, T. (2020). Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. Cancers, 12.","DOI":"10.3390\/cancers12071891"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Belotserkovskaya, E., and Demidov, O. (2021). Mouse Models of CMML. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111510"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Sasaki","year":"2019","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-138680","article-title":"Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial","volume":"136","author":"Itzykson","year":"2020","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/cam4.3774","article-title":"Real-world data of chronic myelomonocytic leukemia: A chinese single-center retrospective study","volume":"10","author":"Ma","year":"2021","journal-title":"Cancer Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"991.e1","DOI":"10.1016\/j.jtct.2021.08.028","article-title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population","volume":"27","author":"Wedge","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbmt.2017.01.078","article-title":"Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia","volume":"23","author":"Liu","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/00498254.2019.1709134","article-title":"Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans","volume":"50","author":"Rioux","year":"2020","journal-title":"Xenobiotica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2019-123854","article-title":"Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)","volume":"134","author":"Steensma","year":"2019","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1038\/s41375-020-0929-3","article-title":"Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia","volume":"34","author":"Kloos","year":"2020","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2021-151707","article-title":"A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed\/Refractory AML Harboring a Ras Pathway-Activating Mutation","volume":"138","author":"Desikan","year":"2021","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.2021013156","article-title":"Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2","volume":"139","author":"Mill","year":"2022","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"801524","DOI":"10.3389\/fonc.2021.801524","article-title":"Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?","volume":"11","author":"Liapis","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"751668","DOI":"10.3389\/fonc.2021.751668","article-title":"Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches","volume":"11","author":"Geissler","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/17\/4107\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:14:59Z","timestamp":1760141699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/17\/4107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":66,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cancers14174107"],"URL":"https:\/\/doi.org\/10.3390\/cancers14174107","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}